Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
- 31 August 2012
- journal article
- review article
- Published by Elsevier BV in Nano Today
- Vol. 7 (4), 367-379
- https://doi.org/10.1016/j.nantod.2012.06.013
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Center for Oncophysics (U54-CA-143837)
- National Science Foundation (1033746)
This publication has 86 references indexed in Scilit:
- Expert opinion: Responsive polymer nanoparticles in cancer therapyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- RNA-Based Therapeutics: Current Progress and Future ProspectsCell Chemical Biology, 2012
- Targeted nanodelivery of drugs and diagnosticsNano Today, 2010
- The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistanceBiomaterials, 2010
- Micro- and nanotechnologies for intelligent and responsive biomaterial-based medical systemsAdvanced Drug Delivery Reviews, 2009
- Co‐delivery of Doxorubicin and Bcl‐2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug‐Resistant Cancer CellsSmall, 2009
- Multifunctional quantum dots for personalized medicineNano Today, 2009
- Molecular imaging and therapy of cancer with radiolabeled nanoparticlesNano Today, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Bcl-2-regulated apoptosis: mechanism and therapeutic potentialCurrent Opinion in Immunology, 2007